WO2023067517 - NOVEL CRYSTALLINE FORMS
National phase entry:
Publication Number
WO/2023/067517
Publication Date
27.04.2023
International Application No.
PCT/IB2022/060055
International Filing Date
19.10.2022
Title **
[English]
NOVEL CRYSTALLINE FORMS
[French]
NOUVELLES FORMES CRISTALLINES
Applicants **
ASSEMBLY BIOSCIENCES, INC.
331 Oyster Point Blvd 4th Floor
South San Francisco, California 94080, US
Inventors
ZONG, Zhixin
c/o Assembly Biosciences, Inc.
331 Oyster Point Blvd
4th Floor
South San Francisco, California 94080, US
WU, Yi
c/o Assembly Biosciences, Inc.
331 Oyster Point Blvd
4th Floor
South San Francisco, California 94080, US
MOHAMMED, Noorullah, Naqvi
c/o Assembly Biosciences, Inc.
331 Oyster Point Blvd
4th Floor
South San Francisco, California 94080, US
WHITE, Nicole
c/o Assembly Biosciences, Inc.
331 Oyster Point Blvd
4th Floor
South San Francisco, California 94080, US
JOHNSON, Mark
c/o Assembly Biosciences, Inc.
331 Oyster Point Blvd
4th Floor
South San Francisco, California 94080, US
WALLACE, Michael
c/o Assembly Biosciences, Inc.
331 Oyster Point Blvd
4th Floor
South San Francisco, California 94080, US
Priority Data
63/257,723
20.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2282 | |
| EPO | Filing, Examination | 14046 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 4530 |
Total: 22024 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure generally relates to novel crystalline forms of a certain compound which are useful as modulators of hepatitis B virus core protein assembly. The present disclosure also relates to identifying suitable solid forms with promising solid state properties for clinical development. The solid state forms disclosed may be used in the manufacture of drug products which may have allosteric effector properties against hepatitis B virus (HBV) core protein (Cp), a protein found as a dimer, a multimer, and as the protein shell of the HBV core. As one example, provided herein is a stable crystalline form which may be useful for treating viral infections, such as hepatitis B.[French]
La présente divulgation concerne de manière générale de nouvelles formes cristallines d'un certain composé qui sont utiles en tant que modulateurs de l'assemblage des protéines du noyau du virus de l'hépatite B. La présente divulgation concerne également l'identification de formes solides appropriées ayant des propriétés d'état solide prometteuses pour le développement clinique. Les formes à l'état solide divulguées peuvent être utilisées dans la fabrication de produits médicamenteux qui peuvent avoir des propriétés effectrices allostériques contre la protéine du noyau (Cp) du virus de l'hépatite B (HBV), une protéine trouvée sous la forme d'un dimère, d'un multimère, ainsi qu'en tant que coque de protéine du noyau de HBV. Par exemple, la présente divulgation concerne une forme cristalline stable qui peut être utile pour traiter des infections virales, telles que l'hépatite B.